FINWIRES · TerminalLIVE
FINWIRES

$AMLX

3 stories mentioning AMLXUpdated 2d ago

Every FINWIRES story that references AMLX, newest first.

Wire

Amylyx Pharmaceuticals Shares Rise After Q2 Loss Narrows

Amylyx Pharmaceuticals (AMLX) shares were up 9.3% in Thursday trading after the company's net loss narrowed in Q2.The company reported a quarterly net loss of $0.39 per diluted share, narrowing from a loss of $0.46 a year earlier.Analysts polled by FactSet expected a loss of $0.36.The company had cash, cash equivalents, and short-term investments of $250.8 million at June 30, expecting a cash runway into 2028.Price: $23.87, Change: $+2.02, Percent Change: +9.24%

$AMLX
Wire

Mizuho Lifts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating

Amylyx Pharmaceuticals (AMLX) has an average rating of buy and mean price target of $23.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $15.76, Change: $-0.55, Percent Change: -3.37%

$AMLX
Wire

Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating

Amylyx Pharmaceuticals (AMLX) has an average rating of buy and mean price target of $23.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $15.78, Change: $-0.53, Percent Change: -3.22%

$AMLX

Track with the FINWIRES app suite

FolioX
FolioX
Track AMLX in your portfolio
WheelAI
WheelAI
Analyze AMLX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on AMLX